ArticleThe World Allergy Organization journal2020
Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized
Article in The World Allergy Organization journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024Guideline
- Review
- House dust mites in three contrasting climatic regions of Saudi Arabia.Experimental & applied acarology · 2026Article
- Diagnostic and therapeutic evaluation ofImmunotherapy · 2025Article
- Efficacy and safety of sublingual immunotherapy using a combination ofThe World Allergy Organization journal · 2025Article
- Brazilian guidelines for allergen immunotherapy in the treatment of allergic asthma.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial.Clinical and translational allergy · 2024Article
- House dust mite allergy in Malaysia: review of research gaps in the current scenario and the way forward.Experimental & applied acarology · 2023Review
- Frequent IgE recognition ofFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSensitization to
objectiveTo assess the therapeutic effect and safety of AIT for asthma using a standardized allergen vaccine of
methodsA double-blind, placebo-controlled Phase II trial was conducted in 35 adults (18 with treatment and 17 with placebo), with mild to moderate asthma, predominantly sensitized to
resultsThe 12-month treatment achieved a significant (p < 0.001) decrease of SMS. Symptom score showed only 41% (CI: 26-61) of placebo values, whereas medication was 34.5% (22.4%-63.3%). Treatment was regarded clinically effective in 67% of patients (OR 32; 95%CI: 17 to 102). The effect size on symptoms and medication was higher than has been reported with equivalent allergen dosages of
conclusionsSubcutaneous AIT with
trial registrationCuban Public Registry of Clinical Trials: RPCEC00000026 (WHO International Clinical Trial Registry Platform ICTRP).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.